0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      ACE Inhibitor versus Beta-Blocker in the Treatment of Essential Hypertension

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          It is to be expected that in the near future the success or failure of antihypertensive substances will be mainly determined by their spectrum of side effects so long as their antihypertensive efficacy is comparable. This double-blind study with crossover of enalapril and atenolol in 58 mild to moderate hypertensive patients is, as far as we know, the first clinical trial evaluating next to the antihypertensive efficacy also compliance and side effects. On the grounds of excellent compliance results (ca. 95%) blood pressure values as well as the incidence of side effects can be assumed to be accurate. Our results show that the antihypertensive efficacy of enalapril is comparable to that of atenolol. The number of patients with side effects did not differ significantly between enalapril and atenolol.

          Related collections

          Author and article information

          Journal
          NEF
          Nephron
          10.1159/issn.1660-8151
          Nephron
          S. Karger AG
          978-3-8055-4710-9
          978-3-318-01616-1
          1660-8151
          2235-3186
          1987
          1987
          05 December 2008
          : 47
          : Suppl 1
          : 90-93
          Affiliations
          aDepartment of Internal Medicine, University Hospital, Zürich, Switzerland; bMedical Polyclinic, University Hospital, Münster, FRG
          Article
          184561 Nephron 1987;47:90–93
          10.1159/000184561
          2827045
          © 1987 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 4
          Categories
          Session IV: Selected Pharmacological Studies

          Cardiovascular Medicine, Nephrology

          Atenolol, Enalapril, Side effects, Compliance, Essential hypertension

          Comments

          Comment on this article